Syndicated report on all published reimbursement decisions for IVD tests in 2018-2020 in European countries with established frameworks for out-patient reimbursement laboratory tests
In-vitro diagnostic tests have a specific reimbursement framework compared with medical devices.
In most of the European countries, IVD tests, that are performed at hospitals are included in DRG tariff, and laboratories are funded using a global budget principle.
However, in out-patient settings, many countries have specific reimbursement frameworks for IVD tests, most commonly using a fee-for-service payment model.
In this report, we summarized reimbursement decisions for IVD tests in 2018, 2019, and 2020 (thee consecutive years) in the countries, where an explicit reimbursement framework exists (Belgium, France, Germany, Netherlands, Switzerland).
Why this report can be of interest to IVD industry?
Reimbursement decisions were collected in the countries, where specific reimbursement frameworks exist (Belgium, France, Germany, Netherlands, Switzerland)
Brief overview of reimbursement framework in each country is provided
All decisions per country are listed in the table format including name of the test, the reimbursement tariff and web-link
Belgium: IVD tests included into INAMI Nomenclature (all relevant chapters)
France: IVD tests included into NABM and RIHN (innovative tests) Nomenclatures, changes in the Supplementary List
Germany: IVD tests included into EBM nomenclature
Netherlands: IVD tests included into reimbursement list of Dutch Health Care Authority (NZa) (tests reimbursed when ordered by GPs)
Switzerland: IVD tests included into List of Analyses (Annex 3 of the KLV List)